ERBB2 and breast carcinoma: pCR predicted better OS for patients with HER2+ breast cancer (HR 0.63, 95 per cent c.i. 0.56 to 0.70, P < 0.001, I2 = 0 per cent; 29 studies) (Fig. 5 and Fig. S11).